Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS Company

ONCSM.E.IS
TREONCO00026

Price

101.80 TRY
Today +/-
+0.07 TRY
Today %
+2.64 %
P

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS stock price

TRY
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS Stock Price History

DateOncosem Onkolojik Sistemler Sanayi ve Ticaret AS Price
10/31/2024101.80 TRY
10/30/202499.15 TRY
10/28/202495.05 TRY
10/25/202494.90 TRY
10/24/202495.65 TRY
10/23/202492.55 TRY
10/22/202494.60 TRY
10/21/202494.05 TRY
10/18/202496.60 TRY
10/17/202497.30 TRY
10/16/202496.10 TRY
10/15/202498.90 TRY
10/14/202497.50 TRY
10/11/2024104.10 TRY
10/10/2024103.30 TRY
10/9/2024107.00 TRY
10/8/2024111.20 TRY
10/7/2024118.60 TRY
10/4/2024122.90 TRY
10/3/2024136.50 TRY

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS’s growth potential.

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS Revenue, EBIT and net profit per share

DateOncosem Onkolojik Sistemler Sanayi ve Ticaret AS RevenueOncosem Onkolojik Sistemler Sanayi ve Ticaret AS EBITOncosem Onkolojik Sistemler Sanayi ve Ticaret AS Net Income
2022140.53 M TRY31.96 M TRY25.49 M TRY
2021127.99 M TRY70.37 M TRY71.73 M TRY
2020101.3 M TRY28.84 M TRY18.71 M TRY

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M TRY)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M TRY)EBIT (M TRY)EBIT MARGIN (%)NET INCOME (M TRY)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
202020212022
101127140
-25.7410.24
37.6269.2943.57
388861
287031
27.7255.1222.14
187125
-294.44-64.79
23.8523.8523.85
---
Details

Keystats

ⓘ

Revenue and Growth

The Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M TRY)RECEIVABLES (M TRY)OTHER REC. (M TRY)INVENTORIES (M TRY)OTHER CURRENT LIAB. (M TRY)CURRENT ASSETS (M TRY)TANGIBLE ASSETS (M TRY)LONG-T. INVEST. (k TRY)LONG-T. REC. (k TRY)INTANGIBLE ASSETS (M TRY)GOODWILL (M TRY)OTHER NON-CURRENT ASSETS (M TRY)NON-CURRENT ASSETS (M TRY)TOTAL ASSETS (M TRY)LIABILITIESCOMMON STOCK (M TRY)ADDITIONAL PAID-IN CAPITAL (M TRY)RETAINED EARNINGS (M TRY)OTHER EQUITY (M TRY)UNREAL. GAINS/LOSSES (M TRY)EQUITY (M TRY)LIABILITIES (M TRY)PROVISIONS (M TRY)OTHER SHORT-TERM LIAB. (M TRY)SHORT-TERM DEBTS (M TRY)LONG-TERM DEBT PORTION (M TRY)SHORT-TERM REC. (M TRY)LONG-T. LIAB. (M TRY)DEFERRED TAXES (M TRY)OTHER LIAB. (M TRY)LONG-T. LIABILITIES (M TRY)DEBT (M TRY)TOTAL CAPITAL (M TRY)
202020212022
     
8.425.7711.68
21.6533.9641.18
1.780.316.48
5.1433.149.61
4.8712.237.95
41.8685.37116.91
86.539.3142.76
00386.37
91.7196.98125.55
0.671.881.05
000
32.96.15
90.2644.1950.47
132.13129.55167.38
     
0.9419.919.9
000
28.0258.984.06
000
45.300
74.2678.8103.96
6.7911.3115.78
2.453.843.77
11.719.5227.14
0.040.147.47
15.029.254.26
35.9944.0758.42
13.284.62.19
6.431.551.08
0.420.541.73
20.126.685
56.1150.7563.42
130.37129.55167.38
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS's financial health and stability.

Assets

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M TRY)DEPRECIATION (M TRY)DEFERRED TAXES (M TRY)CHANGES IN WORKING CAPITAL (M TRY)NON-CASH ITEM (M TRY)PAID INTEREST (M TRY)PAID TAXES (M TRY)NET CASH FLOW FROM OPERATING ACTIVITIES (M TRY)CAPITAL EXPENDITURES (M TRY)CASH FLOW FROM INVESTING ACTIVITIES (M TRY)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M TRY)INTEREST INCOME AND EXPENSES (M TRY)NET DEBT CHANGE (M TRY)NET CHANGE IN EQUITY (M TRY)CASH FLOW FROM FINANCING ACTIVITIES (M TRY)CASH FLOW FROM OTHER FINANCING ACTIVITIES (TRY)TOTAL DIVIDENDS PAID (M TRY)NET CHANGE IN CASH FLOW (M TRY)FREE CASH FLOW (M TRY)SHARE-BASED COMPENSATION (M TRY)
202020212022
187125
5711
00-2
-10-33-18
555
420
000
195121
-16-13-13
-16-37-14
0-240
000
2-140
000
-1-16-1
-4.00-2.00-
000
1-25
3.138.727.09
000

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS stock margins

The Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS's sales revenue. A higher gross margin percentage indicates that the Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS Margin History

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS Gross marginOncosem Onkolojik Sistemler Sanayi ve Ticaret AS Profit marginOncosem Onkolojik Sistemler Sanayi ve Ticaret AS EBIT marginOncosem Onkolojik Sistemler Sanayi ve Ticaret AS Profit margin
202243.62 %22.74 %18.14 %
202169.02 %54.98 %56.05 %
202037.79 %28.47 %18.47 %

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS Stock Sales Revenue, EBIT, Earnings per Share

The Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS earnings per share therefore indicates how much revenue Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS Revenue, EBIT and net profit per share

DateOncosem Onkolojik Sistemler Sanayi ve Ticaret AS Sales per ShareOncosem Onkolojik Sistemler Sanayi ve Ticaret AS EBIT per shareOncosem Onkolojik Sistemler Sanayi ve Ticaret AS Earnings per Share
20225.89 TRY1.34 TRY1.07 TRY
20215.37 TRY2.95 TRY3.01 TRY
20204.25 TRY1.21 TRY0.78 TRY

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS business model

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS is one of the most popular companies on Eulerpool.com.

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS historical P/E ratio, EBIT multiple, and P/S ratio

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS does not pay out any dividends.
Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS does not pay out any dividends.
Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS does not pay out any dividends.
Unfortunately, there are currently no price targets and forecasts available for Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS.

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS shareholders

%
Name
Stocks
Change
Date
66.70860 % Celik (Erol)15,910,00007/25/2024
1

Most common questions regarding Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS

What is the P/E ratio of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS 2024?

The P/E ratio cannot be calculated for Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS at the moment.

What is the P/S ratio of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS 2024?

The P/S cannot be calculated for Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS currently.

What is the Quality Investing of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS?

The Quality Investing for Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS is 3/10.

What is the revenue of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS 2024?

The revenue cannot currently be calculated for Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS.

How high is the profit of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS 2024?

The profit cannot currently be calculated for Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS.

What is the business model of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS

No history available for Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS.

What is the Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS dividend?

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS pays a dividend of 0 TRY distributed over payouts per year.

How often does Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS pay dividends?

The dividend cannot currently be calculated for Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS or the company does not pay out a dividend.

What is the Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS ISIN?

The ISIN of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS is TREONCO00026.

What is the Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS ticker?

The ticker of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS is ONCSM.E.IS.

How much dividend does Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS pay?

Over the past 12 months, Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS is expected to pay a dividend of 0 TRY.

What is the dividend yield of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS?

The current dividend yield of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS is .

When does Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS pay dividends?

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS?

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS paid dividends every year for the past 0 years.

What is the dividend of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS?

For the upcoming 12 months, dividends amounting to 0 TRY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS located?

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS from 11/10/2023 amounting to 0.415 TRY, you needed to have the stock in your portfolio before the ex-date on 11/8/2023.

When did Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS pay the last dividend?

The last dividend was paid out on 11/10/2023.

What was the dividend of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS in the year 2023?

In the year 2023, Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS distributed 0 TRY as dividends.

In which currency does Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS pay out the dividend?

The dividends of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS are distributed in TRY.

All fundamentals about Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS

Our stock analysis for Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.